Basics of Chimeric Antigen Receptor CAR Immunotherapy

Basics of Chimeric Antigen Receptor  CAR  Immunotherapy
Author: Mumtaz Y. Balkhi
Publsiher: Academic Press
Total Pages: 92
Release: 2019-07-31
ISBN 10: 0128197471
ISBN 13: 9780128197479
Language: EN, FR, DE, ES & NL

Basics of Chimeric Antigen Receptor CAR Immunotherapy Book Review:

Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field. Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols Provides unique authority as the editor has worked directly with CARs Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book
Author: Daniel W. Lee,Nirali N. Shah
Publsiher: Elsevier Health Sciences
Total Pages: 244
Release: 2019-11-30
ISBN 10: 0323755976
ISBN 13: 9780323755979
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book Book Review:

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Chimeric Antigen Receptor T Cells

Chimeric Antigen Receptor T Cells
Author: Kamilla Swiech,Kelen Cristina Ribeiro Malmegrim,Virginia Picanco-Castro
Publsiher: Anonim
Total Pages: 329
Release: 2020
ISBN 10: 9781071601464
ISBN 13: 1071601466
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor T Cells Book Review:

Part I Understanding Cancer Immunotherapy A brief Review Part II What is Chimeric Antigen Receptor CAR T Cell Therapy An Emerging Cancer Treatment Modality

Part I  Understanding Cancer Immunotherapy  A brief Review  Part II     What is Chimeric Antigen Receptor  CAR  T  Cell Therapy     An Emerging Cancer Treatment Modality
Author: Dr. Hakim Saboowala
Publsiher: Dr.Hakim Saboowala
Total Pages: 329
Release: 2020-05-12
ISBN 10:
ISBN 13:
Language: EN, FR, DE, ES & NL

Part I Understanding Cancer Immunotherapy A brief Review Part II What is Chimeric Antigen Receptor CAR T Cell Therapy An Emerging Cancer Treatment Modality Book Review:

Part I- Understanding Cancer Immunotherapy: A brief Review. Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapy may work by: Stopping or slowing the growth of cancer cells Stopping cancer from spreading to other parts of the body Helping the immune system work better at destroying cancer cells There are several types of immunotherapy, including: Monoclonal antibodies and tumor-agnostic therapies Non-specific immunotherapies Oncolytic virus therapy T-cell therapy Cancer vaccines Part II- “What is Chimeric Antigen Receptor (CAR) T- Cell Therapy?” An Emerging Cancer Treatment Modality. Chimeric antigen receptor (CAR) T-cell therapy is an emerging cancer treatment modality in which the patients’ own immune cells are collected, genetically engineered to recognize a tumor-related target, expanded in vitro, and then reinfused to produce responses and prevent progression in a variety of malignancies (ie, adoptive cell transfer) Several types of adoptive cell transfer(ACT) are under investigation, but CAR T-cell therapy is the first to enter clinical practice. Like other technologies, CAR-T cell therapy has undergone a long development process in the past. Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. At present, CAR-T cell therapy is developing rapidly, and many clinical trials have been established on a global scale, which has great commercial potential. I have endeavored to compile this E- Booklet into Two Parts i.e. Part I & Part II for better understanding of Chimeric antigen receptor (CAR) T-cell therapy, an emerging cancer treatment modality. In Part I, an effort has been made to describe Cancer Immunotherapy briefly whereas in Part II know about of CAR T-Cell Therapy-the first to enter clinical practice- has been embodied. Further it is attempted to describe toxicity of CAR-T cell therapy briefly and future development and opportunities for immunotherapy. …Dr. H. K. Saboowala. M.B.(Bom) .M.R.S.H.(London)

Immunotherapy

Immunotherapy
Author: Krassimir Metodiev
Publsiher: BoD – Books on Demand
Total Pages: 414
Release: 2017-04-26
ISBN 10: 9535131052
ISBN 13: 9789535131052
Language: EN, FR, DE, ES & NL

Immunotherapy Book Review:

This is another attempt of InTechOpen to continue the dissemination of international knowledge and experience in the field of immunology. The present book includes a number of modern concepts of specialists and experts in the field of immunotherapy, covering the major topics and analyzing the history, current stage, and future ideas of application of modern immunomodulation. It is always a benefit, but also a compliment, to gather a team of internationally distinguished authors and to motivate them to reveal their expertise for the benefit of medical science and health practice. On behalf of all readers, immunologists, immunogeneticists, biologists, oncologists, microbiologists, virologists, hematologists, chemotherapists, health-care experts, as well as students and medical specialists, also on my personal behalf, I would like to extend my gratitude and highest appreciation to InTechOpen for giving me the unique chance to be the editor of this exclusive book.

Immunotherapy Using Chimeric Antigen Receptor Macrophage

Immunotherapy Using Chimeric Antigen Receptor Macrophage
Author: Peng Fei Huang
Publsiher: Anonim
Total Pages: 44
Release: 2019
ISBN 10:
ISBN 13: OCLC:1089833443
Language: EN, FR, DE, ES & NL

Immunotherapy Using Chimeric Antigen Receptor Macrophage Book Review:

Chimeric antigen receptor (CAR) T cell immunotherapy has become one of the most prominent and leading cancer therapies due to its remarkable success in targeting hematological malignancies. Unfortunately, CAR-T cell immunotherapy has not had the same amount of success in solid tumors due to the challenging tumor's immunosuppressive microenvironment. Therefore, we hypothesize the use of macrophages as a vessel for CAR immunotherapy due to their associate with tumors as TAMs and also the tumors ability to secrete various chemokines that can attract myeloid cells to the tumor site. THP-1 a monocytic cell line that represents a monocyte/macrophage model was transduced with an anti-CD19 scFv CAR construct. K562 a leukemia cell line that represents hematological malignancies and H460 a lung cancer cell line that represents solid tumors were transduced to overexpress the surface marker CD19. THP-1 clones expressing the anti-CD19 CAR construct were cocultured with the two tumor cell lines, which demonstrated the ability of the THP-1 CARs to specifically targeted and lysis the tumor cells that overexpressed the CD19 surface marker. Upon CAR activation, THP-1 cells were polarized towards the M1 classical activated phenotype due to the increase in expression of TNF-[alpha], IL-1[beta], IL-6, IL-12[beta], CXCl10, HLA-DR, and CD86. Additionally, THP-1 cells did not show any change in the M2 alternative activated markers of IL10, TFG[beta], CCL18, CCL22, CD206, and CD204 to suggest polarization towards the M2 phenotype. As a result, this study validates the proof of concept that macrophages could potentially be a vessel for CAR immunotherapy.

Developments in T Cell Based Cancer Immunotherapies

Developments in T Cell Based Cancer Immunotherapies
Author: Paolo A. Ascierto,David F. Stroncek,Ena Wang
Publsiher: Humana Press
Total Pages: 305
Release: 2015-11-26
ISBN 10: 3319211676
ISBN 13: 9783319211671
Language: EN, FR, DE, ES & NL

Developments in T Cell Based Cancer Immunotherapies Book Review:

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.

Developing Costimulatory Molecules for Immunotherapy of Diseases

Developing Costimulatory Molecules for Immunotherapy of Diseases
Author: Manzoor Ahmad Mir
Publsiher: Academic Press
Total Pages: 322
Release: 2015-05-25
ISBN 10: 0128026758
ISBN 13: 9780128026755
Language: EN, FR, DE, ES & NL

Developing Costimulatory Molecules for Immunotherapy of Diseases Book Review:

Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases

Targeting the Disialoganglioside GD2 with Chimeric Antigen Receptor T Cells for Immunotherapy in Diffuse Midline Gliomas and Exploration of Neuron opc Synaptic Connectivity in the Context of Adaptive Myelination

Targeting the Disialoganglioside GD2 with Chimeric Antigen Receptor T Cells for Immunotherapy in Diffuse Midline Gliomas and Exploration of Neuron opc Synaptic Connectivity in the Context of Adaptive Myelination
Author: Christopher Mount
Publsiher: Anonim
Total Pages: 329
Release: 2020
ISBN 10:
ISBN 13: OCLC:1155251341
Language: EN, FR, DE, ES & NL

Targeting the Disialoganglioside GD2 with Chimeric Antigen Receptor T Cells for Immunotherapy in Diffuse Midline Gliomas and Exploration of Neuron opc Synaptic Connectivity in the Context of Adaptive Myelination Book Review:

Histone 3 K27M mutated diffuse midline glioma (H3K27M DMG) is a universally fatal pediatric brain tumor. Despite improved understanding of the molecular origins of this disease, translations to improvement in clinical outcomes have yet to materialize. To date, there has been little target exploration for immunotherapy applications in H3K27M DMG. In this thesis, I describe my work that elucidated substantial preclinical efficacy of chimeric antigen receptor (CAR)-bearing T cells targeting the disialoganglioside GD2 as an immunotherapy regimen in patient-derived orthotopic xenograft models of H3K27M DMG. Single-dose systemic administration of GD2-4-1BB-CAR T cells in multiple orthotopic xenograft models of H3K27M DMG achieves potent and lasting antitumor efficacy, including tumor clearance by in vivo bioluminescence imaging and follow-up histology. Treatment-associated toxicity was transient and generally tolerated during the period of peak anti-tumor activity in brainstem orthotopic xenografts. If these results are predictive of human response, GD2-directed CAR T cell therapy in the setting of careful clinical management could have a transformative impact upon H3K27M DMG outcomes. In part two of this thesis, I present data revealing a brain-wide map of afferent neuronal connectivity to oligodendrocyte precursor cells (OPCs). Neurons form bona fide synapses with oligodendrocyte precursor cells (OPCs), but the circuit context of these neuron to OPC synapses remains incompletely understood. Using monosynaptically-restricted rabies virus tracing of OPC afferents, I identified extensive afferent synaptic inputs to OPCs residing in secondary motor cortex and underlying corpus callosum of adult mice. These inputs primarily arise from functionally-interconnecting cortical areas and thalamic nuclei, demonstrating that OPCs in motor-associated territories have synaptic access to brain-wide projection networks engaged in planning and execution of motor tasks. This circuit map is a foundational tool for future studies of context-specific neuron-OPC synapse function.

Chimeric Antigen Receptor CAR T cell Immunotherapy for MUC1 positive Breast Cancer

Chimeric Antigen Receptor  CAR  T cell Immunotherapy for MUC1 positive Breast Cancer
Author: Artemis Gavriil
Publsiher: Anonim
Total Pages: 329
Release: 2018
ISBN 10:
ISBN 13: OCLC:1063625133
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor CAR T cell Immunotherapy for MUC1 positive Breast Cancer Book Review:

Cellular Therapies in Cancer

Cellular Therapies in Cancer
Author: Katy Rezvani,Rohtesh S. Mehta
Publsiher: Frontiers Media SA
Total Pages: 329
Release: 2020-01-16
ISBN 10: 2889633780
ISBN 13: 9782889633784
Language: EN, FR, DE, ES & NL

Cellular Therapies in Cancer Book Review:

The Basics of Cancer Immunotherapy

The Basics of Cancer Immunotherapy
Author: Haidong Dong,Svetomir N. Markovic
Publsiher: Springer
Total Pages: 160
Release: 2018-01-05
ISBN 10: 3319706225
ISBN 13: 9783319706221
Language: EN, FR, DE, ES & NL

The Basics of Cancer Immunotherapy Book Review:

This book provides patients and their physicians (especially “non-oncologist” health care providers) with a clear and concise introduction to cancer immunotherapy, which, unlike traditional forms of cancer therapy, acts by boosting the patient’s own immune system to fight cancer. The unique features of cancer immunotherapy make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize complications of therapy. The patient-friendly, concise, easy-to-understand, and up-to-date knowledge presented in this book will inform patients about the benefits and risks of cancer immunotherapy, and help them and their care providers to understand how immunotherapy would control their unique disease. Researchers and academic professionals in the field of cancer immunotherapy will also find clear and useful information to help them communicate with patients or address unresolved problems. Some key features of the book are: Expertise. All editors and authors are scientists and oncologists specializing in cancer immunotherapy, and are involved in scientific discovery from the early stage of immune-checkpoint inhibitors to today’s daily patient care. Their insights, expertise and experience guarantee the high quality and authority in the science, medicine and practice of cancer immunotherapy. Patient-friendly. This book is written for cancer patients in order to meet their needs when considering immunotherapy. As an educational tool, this book will help the reader balance the risks and benefits based on both science and clinical facts, and therefore to make the best choice in receiving or withdrawing from immunotherapy. Disease Specificity. Cancer is a complicated disease involving multiple stages and pathology. Its response to immunotherapy is individualized and varies depending on cancer types. The authors’ expertise in treating different types of cancers, including melanoma, lung, kidney, bladder, and lymphoma, provides disease-specific insights in applying immunotherapy to each disease.

Cell and Gene Therapies

Cell and Gene Therapies
Author: Miguel-Angel Perales,Syed A. Abutalib,Catherine Bollard
Publsiher: Springer
Total Pages: 288
Release: 2018-11-27
ISBN 10: 3319543687
ISBN 13: 9783319543680
Language: EN, FR, DE, ES & NL

Cell and Gene Therapies Book Review:

In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee.

Cancer Immunotherapy

Cancer Immunotherapy
Author: David B. Teplow
Publsiher: Academic Press
Total Pages: 354
Release: 2019-08-03
ISBN 10: 0128165766
ISBN 13: 9780128165768
Language: EN, FR, DE, ES & NL

Cancer Immunotherapy Book Review:

Cancer Immunotherapy, Volume 165 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to different approaches to cancer immunotherapy, with this release focusing on TNFR2 in cancer immunology and immunotherapy, From the Hellstrom paradox towards cancer cure, CAR T-cell treatment of T-cell malignancy , Immunotherapy of pancreatic cancer, Cancer stem cell immunology/immunotherapy, Cytokine release syndrome, Tumor cell-based mechanisms of resistance to immune attack, and Mushroom compounds in cancer immunotherapy. Includes comprehensive coverage of molecular biology Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided Contains contributions from renowned experts in the field

Translational Research in Breast Cancer

Translational Research in Breast Cancer
Author: Erwei Song,Hai Hu
Publsiher: Springer
Total Pages: 418
Release: 2017-12-28
ISBN 10: 9811060207
ISBN 13: 9789811060205
Language: EN, FR, DE, ES & NL

Translational Research in Breast Cancer Book Review:

This book offers a comprehensive introduction to translational efforts in breast cancer, addressing the latest approaches to precision medicine based on the current state of understanding of breast cancer. With the latest developments in breast cancer research, our understanding of the genomic changes and the oncogenic signaling cascade of breast cancer has made considerable strides. Further, the immuno-environment has been demonstrated as the barrier to clinical cancer. In addition, major advances in cancer biology, immunology, genomics and metabolism have broken new ground for designing therapeutic approaches and selecting appropriate treatments on the basis of more precise information on the individual patient. As a result of these two trends, a clearer picture of the molecular landscape of breast cancers has facilitated the development of diagnostic, prognostic and predictive biomarkers for clinical oncology. All these aspects are addressed in this volume, which offers a comprehensive resource for researchers, graduate students and oncologists in cancer research.

CAR T Cell Therapies for Non Hematopoietic Malignancies Taking Off The Training Wheels

CAR T Cell Therapies for Non Hematopoietic Malignancies  Taking Off The Training Wheels
Author: Avery Dexter Posey, Jr.,John - Maher,Marcela V. Maus
Publsiher: Frontiers Media SA
Total Pages: 329
Release: 2020-04-24
ISBN 10: 2889636879
ISBN 13: 9782889636877
Language: EN, FR, DE, ES & NL

CAR T Cell Therapies for Non Hematopoietic Malignancies Taking Off The Training Wheels Book Review:

Chimeric antigen receptor (CAR) T cell therapies for leukemia (e.g. tisagenlecleucel) and lymphoma (e.g. axicabtagene ciloleucel) have recently received regulatory approval in the United States. Phase I/II trials have demonstrated complete remission of refractory or relapsed tumors in 50% - 94% patients. However, the clinical successes of engineered T cells for the treatment of solid malignancies have thus far been few and far between. Furthermore, several instances of severe and lethal toxicities have arisen due to on-target, off-tumor recognition of antigen by T cell products. Recent advances in phase I trials for solid tumors, as well as in pre-clinical models, have revealed several variables that will be important to consider for the successful use of CAR-T cells in treating solid tumors. These variables include (i) regional versus systemic delivery; (ii) scFv versus ligand interactions; (iii) antigen loss versus escape; (iv) epitope spreading and (v) checkpoint expression on immune cells or tumor cells. Also, there remains outstanding mechanistic questions related to why differences exist in the persistence and tonic signaling of second-generation CD28 versus 4-1BB co-stimulated CAR-T cells. In addition, we are now learning the roles of lympho-depleting regimens (and associated toxicities) in modifying the persistence of engineered T cell therapies. A more comprehensive view of CAR-T cell strategies and important advances, both of pre-clinical and clinical evaluations, in solid tumors is necessary to drive these therapies forward.

The EBMT Handbook

The EBMT Handbook
Author: Enric Carreras,Carlo Dufour,Mohamad Mohty,Nicolaus Kröger
Publsiher: Springer
Total Pages: 702
Release: 2018-12-12
ISBN 10: 3030022781
ISBN 13: 9783030022785
Language: EN, FR, DE, ES & NL

The EBMT Handbook Book Review:

This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers’ knowledge and practice skills.

Immunotherapy in Translational Cancer Research

Immunotherapy in Translational Cancer Research
Author: Laurence J. N. Cooper,Elizabeth A. Mittendorf,Judy Moyes,Sabitha Prabhakaran
Publsiher: John Wiley & Sons
Total Pages: 312
Release: 2018-05-01
ISBN 10: 1118123220
ISBN 13: 9781118123225
Language: EN, FR, DE, ES & NL

Immunotherapy in Translational Cancer Research Book Review:

A guide to state-of-the-art cancer immunotherapy in translational cancer research A volume in the Translational Oncology series, Immunotherapy in Translational Cancer Research explores the recent developments in the role that immunotherapy plays in the treatment of a wide range of cancers. The editors present key concepts, illustrative examples, and suggest alternative strategies in order to achieve individualized targeted therapy. Comprehensive in scope, Immunotherapy in Translational Cancer Research reviews the relevant history, current state, and the future of burgeoning cancer-fighting therapies. The book also includes critical information on drug development, clinical trials, and governmental resources and regulatory issues. Each chapter is created to feature: development of the immunotherapy; challenges that have been overcome in order to scale up and undertake clinical trials; and clinical experience and application of research. This authoritative volume is edited by a team of noted experts from MD Anderson Cancer Center, the world’s foremost cancer research and care center and: Offers a comprehensive presentation of state-of-the-art cancer immunotherapy research that accelerates the pace of clinical cancer care Filled with the concepts, examples, and approaches for developing individualized therapy Explores the breath of treatments that reflect the complexity of the immune system itself Includes contributions from a panel international experts in the field of immunotherapy Designed for physicians, medical students, scientists, pharmaceutical executives, public health and public policy government leaders and community oncologists, this essential resource offers a guide to the bidirectional interaction between laboratory and clinic immunotherapy cancer research.

Chimeric Antigen Receptor T Cell Therapy for the Community Oncologist

Chimeric Antigen Receptor T   Cell Therapy for the Community Oncologist
Author: Anonim
Publsiher: Anonim
Total Pages: 329
Release: 2016
ISBN 10:
ISBN 13: OCLC:1053694839
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor T Cell Therapy for the Community Oncologist Book Review:

Abstract : The field of cancer immunotherapy has rapidly progressed in the past decade as several therapeutic modalities have entered into the clinic. One such immunotherapy that has shown promise in the treatment of cancer is the use of chimeric antigen receptor (CAR)‐modified T lymphocytes. CARs are engineered receptors constructed from antigen recognition regions of antibodies fused to T‐cell signaling and costimulatory domains that can be used to reprogram a patient's T cells to specifically target tumor cells. CAR T‐cell therapy has demonstrated sustained complete responses for some patients with advanced leukemia, and a number of CAR therapies are being evaluated in clinical studies. CAR T‐cell therapy‐associated toxicities, including cytokine release syndrome, macrophage activation syndrome, and tumor lysis syndrome, have been observed and effectively managed in the clinic. In patients with significant clinical responses, sustained B‐cell aplasia has also been observed and is a marker of CAR T‐cell persistence that might provide long‐term disease control. Education on CAR T‐cell therapy efficacy and safety management is critical for clinicians and patients who are considering this novel type of treatment. In the present report, the current landscape of CAR T‐cell therapy, the effective management of patients undergoing treatment, and which patients are the most suitable candidates for current trials are discussed. Implications for Practice: The present report describes the current status of chimeric antigen receptor (CAR) T lymphocytes as an immunotherapy for patients with relapsed or refractory B‐cell malignancies. CAR T cells targeting CD19, a protein expressed on many B‐cell malignancies, typically induce high complete response rates in patients with B‐cell leukemia or lymphoma who have very limited therapeutic options. Recent clinical trial results of CD19 CAR T‐cell therapies and the management of CAR T‐cell‐associated adverse events are discussed. The present report will therefore inform physicians regarding the efficacy and safety of CAR T cells as a therapy for B‐cell malignancies. Abstract : An immunotherapy that has shown promise in cancer treatment is chimeric antigen receptor‐modified (CAR‐modified) T lymphocytes. CARs are engineered receptors constructed from antigen recognition regions of antibodies fused to T‐cell signaling and costimulatory domains that reprogram a patient's T cells to specifically target tumor cells. The current landscape of CAR T‐cell therapy, effective management of patients undergoing treatment, and the most suitable candidates for current trials are discussed.

Esophageal Cancer and Beyond

Esophageal Cancer and Beyond
Author: Jianyuan Chai
Publsiher: BoD – Books on Demand
Total Pages: 92
Release: 2018-11-07
ISBN 10: 1789844126
ISBN 13: 9781789844122
Language: EN, FR, DE, ES & NL

Esophageal Cancer and Beyond Book Review:

Human life relies on two basic supplies from nature: oxygen and food. Oxygen can be utilized directly, but food has to go through a process of digestion to become usable nutrients. The esophagus represents the beginning of this long journey. Because of its critical location, esophageal cancer is one of the deadliest malignancies in the world, and furthermore its incidence has been rising steadily year after year while other cancers are declining. It is predicted that by the year 2035 the esophageal cancer population will increase by 77.4% and become one of top global concerns. This book covers many aspects of esophageal cancer, through which we hope to raise the awareness of professionals as well as non-professionals about this disease.